Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 278
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02412111 | A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor | ||
| NCT01768663 | A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects | ||
| NCT00627926 | A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) | ||
| NCT01890772 | Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1 | ||
| NCT07231419 | Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | ||
| NCT02797132 | Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del | ||
| NCT03625466 | A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del | ||
| NCT00336479 | Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C | ||
| NCT06747572 | Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease | ||
| NCT00395577 | A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702 | ||
| NCT03691779 | Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age | ||
| NCT06832410 | An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant | ||
| NCT07378865 | Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants | ||
| NCT01581138 | VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C | ||
| NCT04618185 | Gut Imaging for Function & Transit in CF - GIFT-CF 3 | ||
| NCT01501383 | A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy | ||
| NCT04138589 | Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function | ||
| NCT06506773 | Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF) | ||
| NCT03304522 | A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy | ||
| NCT00909727 | Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation | ||
| NCT01554085 | First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | ||
| NCT00789126 | Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects | ||
| NCT00973388 | VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers | ||
| NCT05635110 | Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants | ||
| NCT06336096 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine | ||
| NCT06887959 | A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries | ||
| NCT05274269 | Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation | ||
| NCT04254705 | Organoid Study R334W | ||
| NCT01153542 | Study of VX-770 on Desipramine | ||
| NCT06887972 | A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries | ||
| NCT06820307 | Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants | ||
| NCT01144936 | Study of VX-985 in Subjects With Chronic Hepatitis C | ||
| NCT05033080 | A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) | ||
| NCT01531673 | Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation | ||
| NCT04786262 | A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | ||
| NCT05643495 | A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype | ||
| NCT01863238 | An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis | ||
| NCT01807949 | A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation | ||
| NCT05704556 | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment | ||
| NCT02347657 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor | ||
| NCT01467492 | Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C | ||
| NCT05312879 | Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease | ||
| NCT03783286 | Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects | ||
| NCT01888393 | Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects | ||
| NCT03277196 | A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation | ||
| NCT05660538 | Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) | ||
| NCT00865904 | Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation | ||
| NCT02722057 | A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients | ||
| NCT03163511 | A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness | ||
| NCT00251199 | VX-950 and Peginterferon for Hepatitis C |
